Oral rivaroxaban for symptomatic venous thromboembolism.
N Engl J Med. 2010 Dec 23; 363(26):2499-510
Last name Initials , Bauersachs R, Berkowitz SD, Brenner B, ..., Cohen A, Davidson BL, Piovella F, Schellong S. Last name Initials , Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, Gallus AS, Lensing AW, Misselwitz F, Prins MH, Raskob GE, Segers A, Verhamme P, Wells P, Agnelli G, Bounameaux H, Cohen A, Davidson BL, Piovella F, Schellong S. N Engl J Med. 2010 Dec 23; 363(26):2499-510
The article reports that the direct inhibitor of factor Xa, rivaroxaban, offers an improved benefit–risk profile for acute deep vein thrombosis and is a promising alternative to enoxaparin or oral warfarin.
Get instant access to Article Recommendations from more than 5,000 expert scientists and clinical researchers, assisted by 5,000 associates, by taking out a monthly subscription. The first month of your subscription will be free of charge.
Start your personal subscription today.Subscribe for $9.95/month
Send a recommendation to your institution's librarian or information manager to request an extended free trial for all users.Recommend to your Librarian
If you are a librarian or information manager, you may request an extended free trial for your academic or corporate institution.Request an Institutional Trial
your institution might be eligible for free access via our sponsorship scheme. Check our sponsorship page.
If you think you should be able to access this content, please contact us.